Neoadjuvant therapy in pancreatic cancer

Roderick M. Quiros, Kimberly M. Brown, John P. Hoffman

Research output: Contribution to journalReview article

34 Scopus citations

Abstract

Pancreatic cancer is the fourth leading cause of cancer deaths in the United States. Surgical resection offers the only hope of cure, though the addition of chemoradiation in the adjuvant setting has been shown to improve survival over surgery alone. Many patients are unable to receive adjuvant therapy due to prolonged postoperative recovery. For this reason, administration of chemoradiation preoperatively (neoadjuvant) has been proposed as an alternative to postoperative treatment. In patients with resectable disease, neoadjuvant therapy results in similar survivals compared to postoperative therapy, with a greater proportion of patients able to complete treatment. For selected patients with borderline or unresectable disease, neoadjuvant therapy offers the potential for tumor downstaging and increasing the likelihood of a margin-negative resection. This article reviews the use of neoadjuvant therapy in the treatment of pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)267-273
Number of pages7
JournalCancer Investigation
Volume25
Issue number4
DOIs
StatePublished - May 1 2007

Keywords

  • Chemo therapy
  • Induction therapy
  • Neoadjuvant therapy
  • Pancreatic cancer
  • Radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Neoadjuvant therapy in pancreatic cancer'. Together they form a unique fingerprint.

Cite this